VALIRX PLC

Director's Dealing • Jul 7, 2022

National Storage Mechanism | Additional information

RNS Number : 6907R

ValiRx PLC

07 July 2022

7 July 2022

ValiRx PLC ("ValiRx" or the "Company")

Directors' Dealing

ValiRX, a life science company focusing on early-stage cancer therapeutics and women's health, announced 30 June 2022 that certain directors confirmed their intention to participate in the Placing  that was announced on that date.  

The table below sets out details of their participation in the Placing at a price of 10 pence per share.

Director	Ordinary Shares Purchased	Resultant Shareholding	% of Issued Share Capital
Suzanne Dilly	100,000	416,668	0.46%
Martin Lampshire	100,000	144,000	0.16%
Kevin Cox	100,000	372,333	0.41%
Gerry Desler	25,000	128,668	0.14%

*** ENDS ***

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

For more information, please contact:

ValiRx plc Dr Suzanne Dilly, CEO	Tel: +44 (0) 2476 796496 www.valirx.com Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Ludovico Lazzaretti	Tel: +44 (0) 20 7213 088
Cenkos Securities Limited (Joint Broker) Russell Kerr/Michael Johnson (Sales) Callum Davidson/Giles Balleny (Corporate Finance)	Tel: +44 (0) 20 7397 8900
Turner Pope Investments (TPI) Limited  (Joint Broker) James Pope / Andy Thacker	Tel: +44 (0) 20 3657 0050

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process.  We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

a) Suzanne Dilly
b) Martin Lampshire
c) Kevin Cox
d) Gerry Desler

2

Reason for notification

a.

Position/Status

a) Director

b) Director

c) Director

d) Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx PLC

b.

LEI

	213800VQKB9SJCQDET40

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary Shares

ISIN: GB00BLH13C52

b.

Nature of the transaction

Purchase of shares as part of the Placing

c.

Price(s) and volume(s)

Price(s)

Volume(s)

a) 10p
b) 10p
c) 10p
d) 10p

a) 100,000
b) 100,000
c) 100,000
d)  25,000

d.

Aggregated information

- Aggregated Volume

- Price

N/A

e.

Date of the transaction

a) 07/07/2022
b) 07/07/2022
c) 07/07/2022
d) 07/07/2022

f.

Place of the transaction

London, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBGGDRUGGDGDR